Stage IV Oropharyngeal Squamous Cell Carcinoma
4 clinical trials · Condition
◉ Watch Stage IV Oropharyngeal Squamous Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (NCT03422536) | University of Arizona | 2017-12-05 |
| Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery (NCT03342911) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-11-13 |
| Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer (NCT03032250) | Wake Forest University Health Sciences | 2017-05-15 |
| Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer (NCT00458978) | National Cancer Institute (NCI) | 2007-02-01 |
Track Stage IV Oropharyngeal Squamous Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.